High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma
- 30 November 1996
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (12), 2058-2063
- https://doi.org/10.1016/s0959-8049(96)00267-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myelomaBritish Journal of Haematology, 1994
- The Treatment of Multiple MyelomaNew England Journal of Medicine, 1994
- High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patientsBlood, 1993
- Double-intensive therapy in high-risk multiple myelomaBlood, 1992
- High-risk multiple myeloma treated with high-dose melphalan.Journal of Clinical Oncology, 1992
- Imipenem‐cilastatin for empirical therapy in neutropenic patients with fever: An open study in patients with hematologic malignanciesEuropean Journal of Haematology, 1991
- The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's hospital studiesHematological Oncology, 1988
- High dose melphalan for refractory myeloma—the M. D. Anderson experienceHematological Oncology, 1988
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983